Skip to main content

Covista Inc.

corporate_fare Company Profile

Covista Inc.

CVSA·NYSE·Trade & Services·CIK 0000730464

Adtalem Global Education Inc. is a leading healthcare educator in the U.S., incorporated in Delaware in August 1987. The company prepares a diverse talent workforce for the healthcare industry. Adtalem operates five institutions focused on healthcare programs, including nursing, social and behavioral sciences, medicine, and veterinary medicine. These institutions are Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. Together, these institutions serve more than 90,000 students across multiple campuses and online, and have an alumni community of approximately 350,000. Adtalem delivers highly qualified healthcare clinicians to urban and rural communities as a scaled provider to the U.S. healthcare system. The company focuses on expanding access for students through a seamless student experience, innovative learning technologies, and new programs, utilizing its Growth with Purpose operating model. Adtalem aims to offer responsive educational programs supported by exceptional student services. Adtalem reports three segments. The Chamberlain segment includes the operations of Chamberlain University, which provides degree and certificate programs in the nursing and health professions postsecondary education industry.

Covista Inc. (NYSE:CVSA) is a publicly traded company in the Trade & Services sector. Wiseek monitors CVSA SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Covista Reports Strong Revenue and Adjusted Earnings Growth, Proactive Debt Refinancing, and Continued Share Buybacks
  • Strong Q3 Performance Leads Covista to Boost Full-Year Outlook
  • Covista Outlines Long-Term Growth Strategy and FY2029 Financial Targets

Financial Snapshot

Fiscal year ended June 30, 2025
Revenue
$1.79B
Net Income
$237.06M
Diluted EPS
$6.18
Op. Cash Flow
$337.9M
Free Cash Flow
$287.57M
Gross Profit
$1.02B
Operating Income
$341.54M
Cash & Equivalents
$199.6M
Total Debt
$552.67M
Debt / Equity
0.39×
Net Margin
13.3%
Shares Outstanding
35.95M sh
Source: 10-K · filed 2025-08-07 · accession 0001558370-25-010780
Browse all tickers starting with C →
$130 +1.60% today
52-week range · as of 2026-05-07 $86.97 – $156.26
Market cap
$4.37B
Volume
296.1K (1.0× avg)
3-mo avg 294.7K
Live data · 2026-06-14 03:53 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CVSA - Latest Insights

CVSA
May 07, 2026, 4:18 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $119.51
Real-time Price: $130.00 info
Change: +$10.49 (+9%) info
Market Cap: $4.37B info
CVSA
May 07, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $119.51
Real-time Price: $130.00 info
Change: +$10.49 (+9%) info
Market Cap: $4.37B info
CVSA
Apr 09, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $118.00
Real-time Price: $130.00 info
Change: +$12.00 (+10%) info
Market Cap: $4.37B info